Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib

Kidney and Blood Pressure Research

Volumn 35, Issue 6, 2013, Pages 468-476

  Szmit, Sebastian ^a   Zaborowska, Magdalena ^a   Waśko Grabowska, Anna ^a   Zołnierek, Jakub ^a   Nurzyński, Paweł ^a   Filipiak, Krzysztof J ^a   Opolski, Grzegorz ^a   Szczylik, Cezary ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Hypertension; Progression free survival; Renal cell carcinoma; Sorafenib

Indexed keywords

SORAFENIB;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG INDUCED DISEASE; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASES; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERTENSION; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84861988031     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000338175     Document Type: Article

References (33)

1. Ravaud A, Sire M: Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first- and second-line treatment of metastatic renal cell cancer. Ann Oncol 2009; 20: 966-967.
2. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC: Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26: 3709-3714.
3. Rixe O, Billemont B, Izzedine H: Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007; 18: 1117.
4. Bono P, Rautiola J, Utriainen T, Joensuu H: Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol 2011; 50: 569-573.
5. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763-773.
6. Szmit S, Langiewicz P, Zołnierek J, Nurzyński P, Zaborowska M, Filipiak KJ, Opolski G, Szczylik C: Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res 2011; 35: 18-25.
7. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, Trent J 2nd, Champion JC, Durand JB, Lenihan DJ: Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer 2008; 112: 2500-2508.
8. Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S: Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis. Ann Oncol 2009; 20: 1535-1542.
9. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
10. Eskens FA, Verweij J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: A review. Eur J Cancer 2006; 42: 3127-3139.
11. Extermann M: Interaction between comorbidity and cancer. Cancer Control 2007; 14: 13-22.
12. Staehler M, Haseke N, Stadler T, Bader M, Karl A, Becker A, Stief CG: Renal surgery in the elderly: Morbidity in patients aged 1 75 years in a contemporary series. BJU Int 2008; 102: 684-687.
13. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK: Risk factors for congestive heart failure in US men and women: NHANES-I epidemiologic follow-up study. Arch Intern Med 2001; 161: 996-1002.
14. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK: The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562.
15. Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, Sundaresan PR: A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 2011; 67: 751-764.
16. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019.
17. Telli ML, Witteles RM, Fisher GA, Srinivas S: Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008; 19: 1613-1618.
18. Kamada P, Dudek AZ: Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: Report of two cases and literature review. Cancer Invest 2010; 28: 501-504.
19. Wong MK, Jarkowski A: Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: Case report and review of the literature. Pharmacotherapy 2009; 29: 473-478.
20. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204-5212.
21. Weikert S, Boeing H, Pischon T, Weikert C, Olsen A, Tjonneland A, Overvad K, Becker N, Linseisen J, Trichopoulou A, Mountokalakis T, Trichopoulos D, Sieri S, Palli D, Vi neis P, Panico S, Peeters PH, Bueno-de-Mesquita HB, Verschuren WM, Ljungberg B, Hallmans G, Berglund G, González CA, Dorronsoro M, Barricarte A, Tormo MJ, Allen N, Roddam A, Bingham S, Khaw KT, Rinaldi S, Ferrari P, Norat T, Riboli E: Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2008; 167: 438-446.
22. Zhu X, Stergiopoulos K, Wu S: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. Acta Oncol 2009; 48: 9-17.
23. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X: Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 2008; 9: 117-123.
24. Bamias A, Lainakis G, Manios E, Koroboki E, Gyftaki R, Zakopoulos N, Dimopoulos MA: Diagnosis and management of hypertension in advanced renal cell carcinoma: Prospective evaluation of an algorithm in patients treated with sunitinib. J Chemother 2009; 21: 347-350.
25. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SD, Stadler WM, Elliott WJ, Ratain MJ: Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009; 15: 6250-6257.
26. Sane DC, Anton L, Brosnihan KB: Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193-201.
27. Maitland ML, Moshier K, Imperial J, Kasza KE, Karrison T, Elliott W, et al: Blood pressure as a biomarker for sorafenib, an inhibitor of the VEGF signaling pathway. J Clin Oncol 2006; 24(suppl):87, abstr 2035.
28. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O: Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17: 3841-3849.
29. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW: Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-184.
30. Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H, Carducci MA: Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur J Cancer 2011; 47: 1955-1961.
31. Bil J, Zapala L, Nowis D, Jakobisiak M, Golab J: Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Lett 2010; 288: 57-67.
32. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F: Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Mol Cancer Ther 2010; 9: 1092-1099.
33. Guppy A, Jamal-Hanjani M, Pickering L: Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol 2011; 7: 727-736.